IL1RL1 Protein (AA 19-328)

N° du produit ABIN2666553

Détail du produit

Antigène: IL1RL1 (Interleukin 1 Receptor-Like 1 (IL1RL1))

Type de proteíne: Recombinant

Activité biologique: Active

Attributs du protein: AA 19-328

Origine: Humain

Source: HEK-293 Cells

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Pureté: > 95 % , as determined by Coomassie stained SDS-PAGE.

Stérilité: 0.22 μm filtered

niveau d'endotoxine:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Commentaires:

Biological activity: ED50 = 15 - 90 ng/ml, corresponding to a specific activity of 1.1 - 6.6 x 104 units/mg , as determined by inhibition of D10.G4.1 cell proliferation induced by IL-33.

Restrictions: For Research Use only

Stockage

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20 °C to -70 °C. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in 10 mM NaHPO4, 0.3M NaCl, and pH 7.2.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.

Stock: -20 °C

Stockage commentaire: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Détail du antigène

Antigène: IL1RL1 (Interleukin 1 Receptor-Like 1 (IL1RL1))

Autre désignation: IL-1RL1 (IL1RL1 Produits)

Synonymes: DER4 Protein, Fit-1 Protein, Ly84 Protein, ST2L Protein, St2 Protein, St2-rs1 Protein, T1 Protein, T1/ST2 Protein, FIT-1 Protein, IL33R Protein, ST2 Protein, ST2V Protein, FIT1 Protein, interleukin 1 receptor-like 1 Protein, interleukin 1 receptor like 1 Protein, Il1rl1 Protein, IL1RL1 Protein

Sujet: IL-1RL1/ST2 was initially identified in stimulated Balc3T3 cells and is encoded by the IL-1RL1 gene that produces different isoforms by alternative splicing. In humans, four isoforms have been described: a membrane attached ST2L isoform and a soluble protein (sST2/ IL1RL-a) that lacks the transmembrane and cytoplasmic domains, which acts as a natural antagonist of IL-33. The other splice variants are ST2V and ST2LV. ST2V lacks the third immunoglobulin motif and C-terminal portion of ST2 and is mainly present in the gut whereas ST2LV does not have the transmembrane domain. The membrane isoform of ST2L (IL-1RL1) associates with IL-1 receptor accessory proteins (IL-1RAcP) to form the IL-33R. The interaction of IL-33 to its receptor activates NF-kB and MAP kinases and induces Th2 cytokines from in vitro polarized Th2 cells. In vivo, IL-33 promotes the expression of IL-4, IL-5, and IL-13. IL-33 acts as an inflammatory cytokine in Th2-type immune responses during asthma and atopic dermatitis. It is host-protective against helminth infections and reduces atherosclerosis by promoting Th2-type immune responses. Human aortic, coronary artery, and heart microvascular endothelial cells express mRNA for ST2L and sST2 isoforms, acting as a source for sST2 proteins. In fact, sST2 is considered as a prognostic biomarker in myocardial infarction and heart failure. In addition, sST2 has been associated with other human diseases including asthma with acute exacerbation, eosinophilic pneumonia, sepsis and trauma, and exacerbated idiopathic pulmonary fibrosis.

Poids moléculaire: The 550 amino acid recombinant protein has a predicted molecular mass of approximately 62 kDa. The DTT-reduced and non-reduced protein migrate approximately at 100 kDa and 200 kDa by SDS-PAGE. The predicted N-terminal amino acid is Lys.